Dulcis In Fundo Meaning, Drappo Rosso Caravaggio, Case All'asta Falciano Del Massico, Jaguar Land Rover Defender, Orari Traghetti Trapani Favignana, Santa Marina Salina Ristoranti, Oscar Miglior Film 2017, Calendario Maggio 2020 Word, " />

basilea ultime notizie

Ultime Notizie Basilea Di seguito gli articoli di tutte le ultime Basilea news. ROMA - Terremoto in Svizzera, un'apparente anomalia: le Alpi sono zona sismica. Il terremoto di... Articolo completo »   Che ne pensi? Si tratta del più antico e... Articolo completo »   Che ne pensi? Changes in the Board of Directors, Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific, Basilea reports start of clinical phase 1 study in collaboration with the U.S. Il presidente del Sion: "Fermiamo tutto! Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022 Read more Download Jun 24. », Basilea: in consiglio comunale col figlio neonato: cacciata - Succede all'assemblea municipale di Basilea Città. Basilea Pharmaceutica Ltd. Questo è il bollettino di oggi 18 novembre 2020 per, Svizzera, nove positivi nello Zurigo. La polizia ha controllato... Articolo completo »   Che ne pensi? Seleziona una o più cartelle in cui vuoi salvare il documento. info_basilea@basilea.com, Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia, Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer, Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020, Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer, Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020, Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer, Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer, Basilea reports data from poster presentations at ESMO Virtual Congress 2020, Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19, Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China, Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond, Basilea announces data presentations at ESMO Virtual Congress 2020, Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million, Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA), Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds, Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million, Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific, Basilea announces the start of the offer period of its partial repurchase offer for its outstanding convertible bonds due 2022, Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022, Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022, Basilea successfully places CHF 125 million senior convertible bonds, Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million, Basilea enters into sale and leaseback agreement for corporate headquarters building, Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia, Basilea announces appointment of new Head of Global Quality Management, Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting, Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific, Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019, Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium, Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer, Basilea reports total revenue exceeding guidance driven by higher than expected contributions from Cresemba® and Zevtera® in 2019, Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019, Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study, Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this year from Pfizer to Basilea of USD 7 million, Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference, Basilea reports marketing authorization of antifungal Cresemba® in Brazil, Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations, Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer, Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019, Basilea starts phase 1/2 study with derazantinib in urothelial cancer, Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI), Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications, Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting, Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada, Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea reports strong revenue growth and significant pipeline progress for full-year 2018, Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment to Basilea from Pfizer, Basilea announces change in the Management Committee - Adesh Kaul appointed CFO, Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer, Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA), Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018, Basilea presenting at the 37th Annual J. P. Morgan Healthcare Conference - delivering on its strategy, Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea, Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium, Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline, Basilea reports on first Cresemba® approval in MENA region, Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB), Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America, Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma, Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting, Basilea Pharmaceutica: Subscription to Basilea's Press Release Newsletter, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC, Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management, Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders, Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole, Basilea licenses late-stage oncology drug candidate derazantinib from ArQule, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma, Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana, Basilea names Adesh Kaul as new member of its Management Committee, Basilea reports significantly improved financial results in 2017, Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract, Basilea's CEO Ronald Scott will retire.

Dulcis In Fundo Meaning, Drappo Rosso Caravaggio, Case All'asta Falciano Del Massico, Jaguar Land Rover Defender, Orari Traghetti Trapani Favignana, Santa Marina Salina Ristoranti, Oscar Miglior Film 2017, Calendario Maggio 2020 Word,


Lascia un commento